Sanofi-Aventis Czech Republic's operating cash flow stood at CZK -90.1 mil in 2017, up 43.2% when compared to the previous year. Historically, between 2004 - 2017, the firm’s operating cash flow reached a high of CZK 460 mil in 2013 and a low of CZK -685 mil in 2010.
Sanofi-Aventis Czech Republic's total investments stood at CZK -110 mil and accounted for 1.51% of sales in 2017. This is compared to an average of 0.322% as seen over the last five years.
Cash from financing amounted to CZK 189 mil, so the company generated CZK -11.1 mil net cash in 2017.
At the end of 2017, the company had a net debt of CZK 774 mil, or 15.3x of EBITDA and 103% of equity. Net working capital amounted to CZK 1,745 mil, or 24.0% of sales. Cash conversion cycle is negative and reached 89.5 days days in 2017. This means Sanofi-Aventis Czech Republic generates revenue from customers before it has to pay its suppliers for inventory, among other things.
You can see all the company’s data at Sanofi-Aventis Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
